Brief: China NT Pharma Group Says Unit's Drug Shusi Got Approval In Consistency Evaluation
20/02/2020 12:10
Feb 20 (Reuters) - China NT Pharma Group Company Ltd
1011.HK :
* SHUSI, A COMPOUND MEDICINE OF UNIT SUZHOU FIRST
PHARMACEUTICAL,
APPROVED IN CONSISTENCY EVALUATION OF CHINA FDA
* SHUSI IS USED TO TREAT BIPOLAR AFFECTIVE DISORDER; PASSED
HEAD-TO-HEAD COMPARISON CLINICAL TRIALS WITH ORIGINAL DRUG
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2hmHqV
Further company coverage: 1011.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on China NT Pharma Co
See all newsBrief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY
Brief: China NT Pharma Makes Application For Resumption Of Trading On Feb 11
Brief: HKEX Says Trading In Shares Of China NT Pharma Group Company Halted
Brief: China Nt Pharma Group Says To Issue Bonds In Aggregate Principal Amount Of HK$65 Million